1.99
2.45%
-0.05
AN2 Therapeutics Inc stock is currently priced at $1.99, with a 24-hour trading volume of 1.55M.
It has seen a -2.45% decreased in the last 24 hours and a -17.08% declined in the past month.
The chart indicates a potential bearish trend, as the stock is below the $2.06 pivot point. If it approaches the $1.97 support level, significant changes may occur.
Previous Close:
$2.04
Open:
$2.05
24h Volume:
1.55M
Market Cap:
$59.36M
Revenue:
-
Net Income/Loss:
$-64.73M
P/E Ratio:
-0.7107
EPS:
-2.8
Net Cash Flow:
$-53.29M
1W Performance:
-1.49%
1M Performance:
-17.08%
6M Performance:
-88.67%
1Y Performance:
-64.53%
AN2 Therapeutics Inc Stock (ANTX) Company Profile
Name
AN2 Therapeutics Inc
Sector
Industry
Phone
650-331-9090
Address
1800 El Camino Real, Suite D, Menlo Park
AN2 Therapeutics Inc Stock (ANTX) Upgrades & Downgrades
Date | Action | Analyst | Rating Change |
---|---|---|---|
Jul-18-22 | Resumed | Oppenheimer | Outperform |
AN2 Therapeutics Inc Stock (ANTX) Latest News
Views of Wall Street's Leading Experts on AN2 Therapeutics Inc – Sete News - SETE News
SETE News
AN2 Therapeutics Stock (NASDAQ:ANTX), Quotes and News Summary - Benzinga
Benzinga
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround - Yahoo Finance UK
Yahoo Finance UK
Down -5.51% in 4 Weeks, Here's Why AN2 Therapeutics (ANTX) Looks Ripe for a Turnaround - Yahoo Finance
Yahoo Finance
AN2 Therapeutics shares target cut by Evercore ISI on delayed trial data - Investing.com Canada
Investing.com Canada
ANTX Stock Earnings: AN2 Therapeutics Beats EPS for Q1 2024 - MSN
MSN
AN2 Therapeutics Inc Stock (ANTX) Financials Data
AN2 Therapeutics Inc (ANTX) Net Income 2024
ANTX net income (TTM) was -$64.73 million for the quarter ending December 31, 2023, a -58.05% decrease year-over-year.
AN2 Therapeutics Inc (ANTX) Cash Flow 2024
ANTX recorded a free cash flow (TTM) of -$53.29 million for the quarter ending December 31, 2023, a -59.25% decrease year-over-year.
AN2 Therapeutics Inc (ANTX) Earnings per Share 2024
ANTX earnings per share (TTM) was -$2.82 for the quarter ending December 31, 2023, a +40.02% growth year-over-year.
About AN2 Therapeutics Inc
AN2 Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on developing treatments for rare, chronic, and serious infectious diseases. It is developing epetraborole, a once-daily oral treatment for patients with chronic non-tuberculous mycobacterial lung disease. The company was incorporated in 2017 and is headquartered in Menlo Park, California.
Cap:
|
Volume (24h):